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Regulatory Framework 
• Primary responsibility for regulation of clinical trials rests 
with agencies of the U.S. Department of Health and 
Human Services (HHS). 
• These are: 
 Office for Human Research Protections (OHRP) 
 Office of Civil Rights (OCR) 
 Food and Drug Administration (FDA) 
 Office of Research Integrity (ORI) 
 National Institutes of Health (NIH) 
 Centers for Medicare and Medicaid Services (CMS) 
• Primary regulatory concern is: Protection and well-being 




 Three FDA centers regulate medical investigational products 
for human use: 
 Center for Drug Evaluation and Research (CDER) 
 Center for Biologics Evaluation and Research (CBER) 
 Center for Devices and Radiological Health (CDRH) 
 
 FDA’s Office of Regulatory Affairs (ORA) conducts onsite 
bioresearch monitoring inspections of sponsors, PIs and IRBs 
 
 Enforcers:  OIG/DOJ/FBI/State AGs/Health Care Fraud 
Prevention and Enforcement Action Team 
  
Clinical Trial Billing 
• Medicare Coverage Policy 
• NCD 310.1 states that Medicare will cover “routine costs of 
qualifying clinical trials...as well as reasonable and necessary 
items and services used to diagnose and treat complications 
arising from participation in all clinical trials.  All other Medicare 
rules apply.”  -NCD for Routine Cost in Clinical trials (310.1) 
• Many commercial payers follow Medicare 
• The NCD clinical trials policy does not address device 
studies.  Organizations are required to work with their 
Medicare Administrative Contractor (MAC) to determine 
coverage for device studies. 
 
  
States That Require Health Plans to  
Cover Patient Care Costs in Clinical 
Trials 
 
Taken from the National Cancer Institute website, March 2011 
http://www.cancer.gov/clinicaltrials/education/laws 
  
CMS Coverage of Medical Devices 
• WPS Medical Director review not required for  
• Devices approved through FDA pre-market approval process 
• Devices cleared through FDA 510(k) process 
 
• WPS Medical Director approval is required for: 
• FDA-approved IDE Category B devices 
• IRB-approved medical devices 
 
• Devices typically not covered include: 
• FDA-approved Category A devices 
• EXCEPTION may be granted by CMS / WPS Medical Director 
for use in a “life threatening condition.” 
 
  
Category B IDEs 
• FDA-approved IDE Category B devices 
• Routine costs associated with these studies are covered if the 
study is approved by the local Medicare Medical Director 
• If approved, the device can be billed to Medicare if it is not 
provided for free by the sponsor or promised free in the informed 
consent form 
• Medicare coverage is based on the device continuing to meet 
criteria that led to the FDA category designation 
• Payment is limited to or less than what Medicare would have 
paid for a comparable device 
• Payment under Medicare for Category B devices will be based 
on information provided in the IDE submission and clearly stated 
in the IDE exemption letter 
  
Category B IDEs 
• FDA-approved IDE Category B devices 
• Providers are required to identify claims with the proper 
modifiers 
• Claims should include the IDE number assigned to the device 
  
CMS Submission Requirements 
• Provider name and number (for Part A it would be the 
institution name and number, for Part B it would be the PI 
provider number along with the mailing address) 
• For Part B, all co-investigators that will bill for services must also be 
listed with the submission. 
• Name and Number of the investigational device(s) utilized in the 
trial. 
• A narrative description of the device(s).  
• Signed copy of the FDA-approval letter demonstrating category A or 
B IDE status. 
 
  
CMS Submission Requirements 
• The FDA letter containing the most current approved number 
of institutions and subjects (may be 2 separate letters). 
• Number of Medicare cases planned for the study at the 
specific institution. 
• A copy of the final protocol from the sponsor.  
• Additional items to be maintained at the site and readily 
available 
– The agreement between the company or manufacturer and the 
provider, furnishing the details of the provider participation. 
– At least 2 peer-review publications. 
– Any product literature illustrating the device and/or procedure. 
– IRB-approval for the protocol to be carried out at the institution.  
 
  
BJC/ WUSM Approval Process 
Step 1:  Notification of Device Trial  
• WUSM Contracts Department notifies BJH Research Billing Compliance 
and the WU Clinical Research Billing Support office via e-mail of any new 
device trial as it comes to that office. Documents available at that time are 
attached.  
• Clinical Research Billing Support-Secretary (Jan Light) notifies BJH 
Research Compliance (Darlene Szczuka) via e-mail when she receives an 
IRB application for a new device trial and forwards the HRPO approval. 
Kelly Granda is copied on this e-mail transmission. 
 
Step 2: Communication with Study Team 
• Upon receiving knowledge of the trial, BJH will send an e-mail to the study 
coordinator informing them that she will be gathering the required 
documents and will send one packet including those documents and the 
request for coverage letter from both institutions. She will request the letter 
from the physician (or representative) be sent to her for mailing. 
  
BJC/ WUSM Approval Process 
Step 3: Gathering Documents 
• BJH acquires required documents from CCS contracts, CCS Clinical 
Research Billing Support, department coordinators, and sponsors as 
appropriate.    
 
Step 4: Sending the packet to WPS 
• Upon receipt of all necessary documents and letters, BJH will write a cover 
letter to Dr. Stephen Boren (CMS) informing him that the packet includes 
requests from both entities. This letter is scanned and e-mailed to the 
coordinator listed on the device form along with the following individuals:  
the coordinator, the PI, Denise McCartney, Melanie Rowe, Deb Wierciak, 
William Woloszyn, and if the trial is within the Department of Surgery, Kathy 
Hoertel .  
  
BJC/ WUSM Approval Process 
Step 5: Review Process issues 
• Any requests or questions coming from WPS will be directed to the 
appropriate entity. 
 
Step 6: WPS Approval letter receipt 
• BJH will inform the coordinator when approval is granted and will request 
that WU reciprocate and send the WU approval letter to her.  
  
Quick Summary 
• Device Trial Coverage: Medicare requires the MAC 
Medical Director’s approval 
– Category A IDE: when studying a life-threatening condition 
– Category B IDE: when Medicare contractor approves coverage 
– PMA: generally covered with approval (if MAC requests) 
• Note: Carotid artery stent PMAs must be submitted 
– Labeled Use: generally covered with approval (if MAC requests) 
  
Questions 
For More Information Contact: 
 
Carlos Brown @ 362-0938 
or 
Yi Zhang @ 362-6864 
